Beta-adrenoblockers in patients with metabolic syndrome
Aim. To study the effects of 16-week bisoprolol therapy on 24-hour blood pressure monitoring (BPM) data, carbohydrate and lipid metabolism, tissue insulin sensitivity, and cerebral perfusion (CB) in patients with mild to moderate arterial hypertension (AH) and metabolic syndrome (MS).Material and me...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2008-04-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1330 |
| _version_ | 1827064035406774272 |
|---|---|
| author | V. B. Mychka G. Kh. Sharipova N. V. Flegontova I. E. Chazova |
| author_facet | V. B. Mychka G. Kh. Sharipova N. V. Flegontova I. E. Chazova |
| author_sort | V. B. Mychka |
| collection | DOAJ |
| description | Aim. To study the effects of 16-week bisoprolol therapy on 24-hour blood pressure monitoring (BPM) data, carbohydrate and lipid metabolism, tissue insulin sensitivity, and cerebral perfusion (CB) in patients with mild to moderate arterial hypertension (AH) and metabolic syndrome (MS).Material and methods. The study included 30 patients with I-II AH and MS receiving bisoprolol (5 mg/d). At baseline and after 3 months of the treatment, levels of total cholesterol (CH), high and low-density CH, triglycerides, fasting and postprandial glucose, and insulin were measured; 24-hour BPM and CP assessment were performed.Results. Bisoprolol monotherapy was associated with substantial reduction in nighttime mean maximal and minimal systolic and diastolic BP, without significant changes in lipid profile, fasting and postprandial glycemia, or CP, comparing to baseline levels.Conclusion. Due to its metabolically neutral effects, bisoprolol could be recommended in patients with carbohydrate and lipid metabolism disturbances. |
| first_indexed | 2024-04-10T03:39:37Z |
| format | Article |
| id | doaj.art-8b12a0e975d4465aab860453f413eb47 |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2025-03-19T22:40:44Z |
| publishDate | 2008-04-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-8b12a0e975d4465aab860453f413eb472024-10-17T12:21:26Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252008-04-017255591040Beta-adrenoblockers in patients with metabolic syndromeV. B. Mychka0G. Kh. Sharipova1N. V. Flegontova2I. E. Chazova3A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. MoscowA.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. MoscowA.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. MoscowA.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. MoscowAim. To study the effects of 16-week bisoprolol therapy on 24-hour blood pressure monitoring (BPM) data, carbohydrate and lipid metabolism, tissue insulin sensitivity, and cerebral perfusion (CB) in patients with mild to moderate arterial hypertension (AH) and metabolic syndrome (MS).Material and methods. The study included 30 patients with I-II AH and MS receiving bisoprolol (5 mg/d). At baseline and after 3 months of the treatment, levels of total cholesterol (CH), high and low-density CH, triglycerides, fasting and postprandial glucose, and insulin were measured; 24-hour BPM and CP assessment were performed.Results. Bisoprolol monotherapy was associated with substantial reduction in nighttime mean maximal and minimal systolic and diastolic BP, without significant changes in lipid profile, fasting and postprandial glycemia, or CP, comparing to baseline levels.Conclusion. Due to its metabolically neutral effects, bisoprolol could be recommended in patients with carbohydrate and lipid metabolism disturbances.https://cardiovascular.elpub.ru/jour/article/view/1330arterial hypertensionmetabolic syndromecerebral perfusionbisoprolol |
| spellingShingle | V. B. Mychka G. Kh. Sharipova N. V. Flegontova I. E. Chazova Beta-adrenoblockers in patients with metabolic syndrome Кардиоваскулярная терапия и профилактика arterial hypertension metabolic syndrome cerebral perfusion bisoprolol |
| title | Beta-adrenoblockers in patients with metabolic syndrome |
| title_full | Beta-adrenoblockers in patients with metabolic syndrome |
| title_fullStr | Beta-adrenoblockers in patients with metabolic syndrome |
| title_full_unstemmed | Beta-adrenoblockers in patients with metabolic syndrome |
| title_short | Beta-adrenoblockers in patients with metabolic syndrome |
| title_sort | beta adrenoblockers in patients with metabolic syndrome |
| topic | arterial hypertension metabolic syndrome cerebral perfusion bisoprolol |
| url | https://cardiovascular.elpub.ru/jour/article/view/1330 |
| work_keys_str_mv | AT vbmychka betaadrenoblockersinpatientswithmetabolicsyndrome AT gkhsharipova betaadrenoblockersinpatientswithmetabolicsyndrome AT nvflegontova betaadrenoblockersinpatientswithmetabolicsyndrome AT iechazova betaadrenoblockersinpatientswithmetabolicsyndrome |